 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
ABIOMED, Inc. (ABMD) researches, develops, and sells medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients.
The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump.
It also manufactures and sells AB5000 circulatory support system for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. In addition, the company provides Symphony, a synchronized minimally invasive implantable cardiac assist device designed to treat chronic patients with moderate heart failure by improving patient hemodynamics.
Further, it engages in the research, development, prototyping, and production of a percutaneous expandable catheter pump, which enhances blood circulation from the heart with an external drive shaft.
The company sells its products through direct sales and clinical support personnel in the United States, Germany, France, Canada, Japan, and the United Kingdom.
Shares have formed a bullish "cup and handle" and are expected to head higher out of this formation. Note the 200-day moving average on the stock.
52-Weeks Trading Range: $21.84 - $110.68
Entry Point: $96.50
Stop Loss: $91.55
Target Price: $106.15
ABMD closed at $107.00
